Local Chemotherapy With Conjunctival Bevacizumab Injections In Case Of Lymphoma Tumor.

Isolated conjunctival lymphoma accounts for approximately 5-25% of ocular adnexal lymphomas (OAL), the average age of onset. Bilateral involvement occurs in 10-15% of cases, there is a slight predilection of males (54% men vs. 46% women), and the average age of diagnosis is approximately 35 years old. The risk of spreading is about 37%, during five years 10-15%, and for ten years 28%. Different therapeutic approaches exist, with no consensus for the gold standard.This report is the first case report of treatment of the recurrence after surgical excision with multiple Avastin-Bevacizumab injections (Roche 2,5 mg/0,1 mL) directly into the tumor area.

Lymphoma is the most common type of blood cancer. It affects white blood cells-lymphocytes when at least one condition is present: faster replication of abnormal cells, longer life than normal lymphocytes. Non-Hodgkin Lymphoma (NHL) is the most common type among three significant categories of lymphoma. Approximately eight percent of all NHL constitutes Marginal Zone Lymphoma (MZL). It occurs more commonly in women at the average age of 60 years.

Isolated conjunctival lymphoma accounts for approximately 5-25% of ocular adnexal lymphomas (OAL). Bilateral involvement occurs in 10-15% of cases, there is a slight predilection of males (54% men vs. 46% women), and the average age of diagnosis is approximately 35 years old. The risk of spreading is about 37%, during five years 10-15%, and for ten years 28%.  Different therapeutic approaches exist, with no consensus for the gold standard. This report is the first case report of treatment of the recurrence after surgical excision with multiple Avastin-Bevacizumab injections (Roche 2,5 mg/0,1 mL) directly into the tumor area. After the initial three-monthly injections of 0,1ml/2,5 mg, we gave another seven injections (6,9,11,13,15, and 17 months). The lesion ultimately disappeared. No systemic or local adverse events occurred during and after treatment. Five years after the ending of therapy, there is no evidence of local or systemic involvement.

Bevacizumab (Avastin) injections should be considered a safe and effective treatment option in cases of lymphangiomas with evidence of prominent vascular components. We didn't find any systemic or local activities in five years of observation. It is also worth mentioning that anterior OCT is a potent tool for non-invasive diagnosing and follow-up. In this case, there is an excellent correlation between clinical and OCT findings.